Innate Pharma S.A. is a biopharmaceutical Company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.
The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. The mechanisms controlling these cells were described in the late 90’s notably by the teams of the scientists who founded Innate Pharma.
It is on the basis of this science that Innate Pharma develops drug candidates with immuno-stimulating properties for cancer and with immuno-blocking properties in inflammatory conditions. Furthermore, many of the ligands for innate immunity receptors are expressed on cancer cells, opening the way to the development of directly cytotoxic antibodies.
Three product-candidates resulting from the Company’s research platform are currently being tested in clinical trials; two of these by our partners, Bristol-Myers Squibb and Novo Nordisk A/S.
Innate Pharma’s key expertise is in immunopharmacology and antibody technology. The Company has a large panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates. In addition, Innate Pharma has access to a very large set of unique research tools in cellular immunology through its worldwide network of scientific collaborations.
Incorporated in 1999 and Listed on Euronext-Paris, Innate Pharma is based in Marseille, France. It had 85 employees as at March 31, 2014.